- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03991741
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
December 1, 2022 updated by: Gregory Daniels
Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells.
This is called transfer of autologous (they came from you) tumor infiltrating lymphocytes (the cells that have been grown in the laboratory.
Participants getting these cell infusions will also be treated with interleukin-2 (IL-2).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gregory Daniels, MD, PhD
- Phone Number: 858-534-3804
- Email: gdaniels@ucsd.edu
Study Contact Backup
- Name: Catherine O'neil
- Email: croneil@health.ucsd.edu
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- UC San Diego Moores Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a histologically confirmed diagnosis of head and neck squamous cell carcinoma OR metastatic cutaneous or mucosal melanoma measurable per RECIST.
Progressive squamous cell cancer of the head and neck or metastatic melanoma since prior systemic treatment and who are:
- Not candidates for known curative intent therapy.
- Progressed following at least one prior systemic therapy.
- Have advanced melanoma unresectable stage III or stage IV
- Have advanced head and neck recurrent or metastatic disease
- Have no more than 3 brain metastases. Note: If lesions are symptomatic or ≥ 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible.
- Life expectancy of greater than 3 months.
- ECOG Performance Status of 0 or 1.
- Adequate organ and marrow function
- Seronegative for HIV antibody.
- Seronegative for Hepatitis B antigen, or Hepatitis C antibody or antigen.
- More than four weeks has elapsed since the patient received any prior systemic therapy at the time of enrollment.
- Patient has stable or progressing disease after at least one prior treatment.
- Six weeks or more have elapsed since the patient received any prior anti-CTLA4 antibody therapy
Exclusion Criteria:
- Currently using investigational agents.
- Had prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen.
- Patient is a female of child-bearing potential who is pregnant or breastfeeding
- Patient requires immune suppressive therapy including but not limited to greater than physiologic steroid replacement.
- Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
- Patient has any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).
- Patient has opportunistic infections.
- Patient has a history of coronary revascularization or ischemic symptoms.
- Patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: melanoma
|
Autologous TILs
720,000 IU/kg every 8 hours for up to 15 doses
|
EXPERIMENTAL: head and neck cancer
|
Autologous TILs
720,000 IU/kg every 8 hours for up to 15 doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose Limiting Toxicity
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
treatment related Adverse Events
Time Frame: 2 months
|
2 months
|
Overall Response Rate
Time Frame: 2 months
|
2 months
|
Progression Free Survival
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 7, 2020
Primary Completion (ANTICIPATED)
August 1, 2024
Study Completion (ANTICIPATED)
August 1, 2026
Study Registration Dates
First Submitted
April 10, 2019
First Submitted That Met QC Criteria
June 18, 2019
First Posted (ACTUAL)
June 19, 2019
Study Record Updates
Last Update Posted (ACTUAL)
December 5, 2022
Last Update Submitted That Met QC Criteria
December 1, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Head and Neck Neoplasms
- Recurrence
- Melanoma
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- 160710
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Melanoma
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
Elizabeth DavisBristol-Myers SquibbTerminatedMetastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II ExpressionUnited States
-
Provectus Biopharmaceuticals, Inc.Active, not recruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the LiverUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
Clinical Trials on Autologous Tumor Infiltrating Lymphocytes
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Tongji Hospital; Qilu Hospital of Shandong UniversityNot yet recruitingTumor Infiltrating Lymphocytes
-
Suzhou BlueHorse Therapeutics Co., Ltd.RecruitingMelanoma | Non Small Cell Lung Cancer | Cervical CarcinomaChina
-
Zhiyong HuangWuhan Elongevity Technology Co., Ltd.Recruiting
-
Shanghai OriginCell Therapeutics Co., Ltd.Not yet recruitingCarcinoma, Non-Small-Cell Lung
-
Henan Cancer HospitalUnknown
-
Fudan UniversityCellular Biomedicine Group Ltd.Recruiting
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Iovance Biotherapeutics, Inc.CompletedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Peking University Cancer Hospital & InstituteUnknown
-
Iovance Biotherapeutics, Inc.RecruitingMetastatic Non Small Cell Lung CancerUnited States, Canada, Germany, Netherlands